CSPC Pharmaceutical Group Limited (FRA:CVGU)
Germany
· Delayed Price · Currency is EUR 3.220
-0.020 (-0.62%)
At close: Dec 4, 2025
Revenue by Geography
Fiscal year is January - December.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2019 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2019 - 2020 |
| Mainland China Revenue | 21.40B | 25.11B |
Log In |
Log In |
Log In | Upgrade
|
| Other Asian Regions Revenue | 1.20B | 1.18B |
Log In |
Log In |
Log In | Upgrade
|
| North America Revenue | 1.38B | 853.04M |
Log In |
Log In |
Log In | Upgrade
|
| Americas Revenue | - | - |
Log In |
Log In |
Log In | Upgrade
|
| Europe Revenue | 1.41B | 1.31B |
Log In |
Log In |
Log In | Upgrade
|
| Other Geographies Revenue | 604.24M | 553.88M |
Log In |
Log In |
Log In | Upgrade
|
| Other Geographies Revenue (Pre-FY2023 Reporting) | - | - |
Log In |
Log In |
Log In | Upgrade
|
Revenue
Fiscal year is January - December.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2019 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2019 - 2020 |
| Nervous System Revenue | 8.16B | 9.65B |
Log In |
Log In |
Log In | Upgrade
|
| Oncology Revenue | 2.77B | 4.40B |
Log In |
Log In |
Log In | Upgrade
|
| Anti-Infectives Revenue | 3.44B | 4.09B |
Log In |
Log In |
Log In | Upgrade
|
| Cardiovascular Revenue | 1.72B | 2.08B |
Log In |
Log In |
Log In | Upgrade
|
| Respiratory System Revenue | 1.02B | 1.20B |
Log In |
Log In |
Log In | Upgrade
|
| Digestion and Metabolism Revenue | 932.10M | 1.05B |
Log In |
Log In |
Log In | Upgrade
|
| Other Therapeutic Areas Revenue | 1.31B | 1.26B |
Log In |
Log In |
Log In | Upgrade
|
| Total Finished Drugs Revenue | 19.34B | 23.72B |
Log In |
Log In |
Log In | Upgrade
|
| Vitamin C Revenue | 2.21B | 1.99B |
Log In |
Log In |
Log In | Upgrade
|
| Antibiotics Revenue | 1.60B | 1.59B |
Log In |
Log In |
Log In | Upgrade
|
| Total Bulk Products Revenue | 3.80B | 3.58B |
Log In |
Log In |
Log In | Upgrade
|
| Licence Fee Income | 1.09B | 17.83M |
Log In |
Log In |
Log In | Upgrade
|
| Functional Food and Others Revenue | 1.76B | 1.69B |
Log In |
Log In |
Log In | Upgrade
|
EBIT
Fiscal year is January - December.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2019 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2019 - 2020 |
| Finished Drugs Segment Profit | 3.73B | 4.83B |
Log In |
Log In |
Log In | Upgrade
|
| Vitamin C Segment Profit | 324.64M | 211.28M |
Log In |
Log In |
Log In | Upgrade
|
| Antibiotics Segment Profit | 258.20M | 299.18M |
Log In |
Log In |
Log In | Upgrade
|
| Total Bulk Products Segment Profit | 582.84M | 510.45M |
Log In |
Log In |
Log In | Upgrade
|
| Functional Food and Others Segment Profit | 339.79M | 305.29M |
Log In |
Log In |
Log In | Upgrade
|